Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 6/20 | 0.46 |
| ▸ | MMP13 | P45452 | 5/20 | 0.46 |
| ▸ | MMP3 | P08254 | 4/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | MMP7 | P09237 | 2/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076159 | 0.82 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1 | |
| SCHEMBL22501273 | 0.77 | KMT2A (0.77) | MEN1KMT2AAIMP2ALDH1A1F2 | |
| SCHEMBL30964136 | 0.77 | KMT2A (0.77) | MEN1KMT2AAIMP2ALDH1A1F2 | |
| SCHEMBL22500499 | 0.76 | KMT2A (0.76) | MEN1KMT2AAIMP2ALDH1A1F2 | |
| SCHEMBL22500267 | 0.76 | KMT2A (0.76) | MEN1KMT2AAIMP2ALDH1A1F2 | |
| SCHEMBL22501264 | 0.75 | KMT2A (0.74) | MEN1KMT2AAIMP2ALDH1A1F2 | |
| SCHEMBL22500547 | 0.75 | KMT2A (0.98) | MEN1KMT2AAIMP2ALDH1A1F2 | |
| SCHEMBL22501084 | 0.75 | KMT2A (0.98) | MEN1KMT2AAIMP2ALDH1A1F2 | |
| SCHEMBL22500549 | 0.75 | KMT2A (0.98) | MEN1KMT2AAIMP2ALDH1A1F2 | |
| SCHEMBL22500262 | 0.74 | KMT2A (1.00) | MEN1KMT2AAIMP2ALDH1A1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | MEN1 855/4885KMT2A 1619/4885AIMP2 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.